279 related articles for article (PubMed ID: 26678395)
1. A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
Taki S; Kamada H; Inoue M; Nagano K; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S
PLoS One; 2015; 10(12):e0144712. PubMed ID: 26678395
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3.
Kamada H; Taki S; Nagano K; Inoue M; Ando D; Mukai Y; Higashisaka K; Yoshioka Y; Tsutsumi Y; Tsunoda S
Biochem Biophys Res Commun; 2015 Jan; 456(4):908-12. PubMed ID: 25528586
[TBL] [Abstract][Full Text] [Related]
3. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
[TBL] [Abstract][Full Text] [Related]
4. Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer.
Zhou Y; Gou LT; Guo ZH; Liu HR; Wang JM; Zhou SX; Yang JL; Li XA
Mol Med Rep; 2015 Jul; 12(1):147-54. PubMed ID: 25760691
[TBL] [Abstract][Full Text] [Related]
5. Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.
Nagano K; Maeda Y; Kanasaki S; Watanabe T; Yamashita T; Inoue M; Higashisaka K; Yoshioka Y; Abe Y; Mukai Y; Kamada H; Tsutsumi Y; Tsunoda S
J Control Release; 2014 Sep; 189():72-9. PubMed ID: 24946238
[TBL] [Abstract][Full Text] [Related]
6. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
7. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
8. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
9. Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct.
Hammond SA; Lutterbuese R; Roff S; Lutterbuese P; Schlereth B; Bruckheimer E; Kinch MS; Coats S; Baeuerle PA; Kufer P; Kiener PA
Cancer Res; 2007 Apr; 67(8):3927-35. PubMed ID: 17440108
[TBL] [Abstract][Full Text] [Related]
10. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.
Cha JH; Chan LC; Wang YN; Chu YY; Wang CH; Lee HH; Xia W; Shyu WC; Liu SP; Yao J; Chang CW; Cheng FR; Liu J; Lim SO; Hsu JL; Yang WH; Hortobagyi GN; Lin C; Yang L; Yu D; Jeng LB; Hung MC
J Biol Chem; 2022 Apr; 298(4):101817. PubMed ID: 35278434
[TBL] [Abstract][Full Text] [Related]
11. A fully human CD19/CD3 bi-specific antibody triggers potent and specific cytotoxicity by unstimulated T lymphocytes against non-Hodgkin's lymphoma.
Zhou Y; Gou LT; Mu B; Liao WC; He J; Ma C; Yao YQ; Yang JL
Biotechnol Lett; 2012 Jul; 34(7):1183-91. PubMed ID: 22421972
[TBL] [Abstract][Full Text] [Related]
12. [Production, identification and redirected cytotoxicity of CD3/CD19 bispecific monoclonal antibody].
Chen X; Shen D; Sun T; Bai J; Huang L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Oct; 20(5):351-6. PubMed ID: 11717991
[TBL] [Abstract][Full Text] [Related]
13. [Development of a Fundamental Technology to Seek Drug Targets, and Its Application to Cancer Targeting Therapy].
Nagano K; Higashisaka K; Tsunoda SI; Tsutsumi Y
Yakugaku Zasshi; 2018; 138(7):903-909. PubMed ID: 29962467
[TBL] [Abstract][Full Text] [Related]
14. Eph receptor A10 has a potential as a target for a prostate cancer therapy.
Nagano K; Yamashita T; Inoue M; Higashisaka K; Yoshioka Y; Abe Y; Mukai Y; Kamada H; Tsutsumi Y; Tsunoda S
Biochem Biophys Res Commun; 2014 Jul; 450(1):545-9. PubMed ID: 24924629
[TBL] [Abstract][Full Text] [Related]
15. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
16. [Study on p53 tetramerization domain in improving functional affinity and biological activity of antibody].
Wang D; Wu GJ; Tan JM; Wang H
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):479-82. PubMed ID: 15854555
[TBL] [Abstract][Full Text] [Related]
17. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
18. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary metastases neutralization and tumor rejection by in vivo administration of beta glucan and bispecific antibody.
Penna C; Dean PA; Nelson H
Int J Cancer; 1996 Jan; 65(3):377-82. PubMed ID: 8575861
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
